In elderly or medically frail patients with advanced/unresectable cutaneous squamous cell carcinoma, does the lower rate of severe grade ≥3 immune-related adverse events reported with cosibelimab lead you to favor it over established anti-PD-1 agents (e.g., cemiplimab)?

While efficacy and safety data from cosibelimab clinical trials are promising, we don’t have any head-to-head trials comparing ICI treatments for cSCC. The rates of AEs and SAEs have decreased in all of the ICI clinical trials since the initial sentinel trials, possibly in part due to improved recog...